Biography

1.Research Interest

Clinical and basic research on liver diseases

2. Educational Background

1995.9–1999.7, Capital Medical University, Internal medicine, Ph.D& M.D.

1991.9–1994.7, Tianjin Medical University, Internal medicine,Master's degree

1984.9–1989.7, Tongji Medical College of HUST, Clinical Medicine, Bachelor's degree

2004.9 – 2005.9, Mayo Clinic, SRF

3.Work Experience

1989.8-1994.7, Tianjin Third Central Hospital,Department of Hepatology and Gastroenterology, physician

1994.7-1999.7, Tianjin Third Central Hospital, Department of Hepatology and Gastroenterology, Attending Doctor

1999.7-2004.11, Tianjin Third Central Hospital,Department ofHepatology and Gastroenterology, Associate Chief physician

2004.11-present, Tianjin Third Central Hospital, Department of Hepatology and Gastroenterology, Chief physician, professor

2005.12-2013.9, Tianjin Third Central Hospital, Department of Hepatology and Gastroenterology, Chairman

2006.11- present, Tianjin Third Central Hospital, Vice president of hospital

4.Major Professional memberships

Standing membership of Chinese Society of Hepatology and leader of severe liver disease and artifical liver group，CSH. Chairman，Tianjin Society of Hepatology.

Vice president of China Network for Severe Liver Diseases.Standing membership of infection disease branch,Chinese Medical Doctor Association,etc.

5. Major Awards and Achievements

Six times for Tianjin Scientific and Technological Progress Award.

Tianjin outstanding contribution expert.

6. Major Academic papers published in the past five years

(1) Wang F, Liu H, Wang F, Xu R, Wang P, Tang F, Zhang X, Zhu Z, Lv H, Han T. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep. 2018, 17(4): 5213-5221.

(2) Jiang Y, Han T, Zhang ZG, Zhang Y, Qi FX. Serum thymosin beta4as a noninvasive biomarker in patients with nonalcoholicsteatohepatitis. Rev Esp Enferm Dig. 2018, 110(1): 19-24.

(3) Zhang K, Han XH, Zhang Z, Zheng LN, Hu ZM, Yao QB, Cui HM, Shu GM, Si MJ, Li C, Sh ZM, Chen T, Han YW, Chang YN, Yao Z, Han T&Hong W. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβand Notch pathways. Nature Communications. 2017, 8(1): 144.

(4) Ye Q, Yin W, Zhang L, Xiao H, Qi Y, Liu S, Qian B, Wang F, Han T. The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis. PloS One, 2017, 12(4): e0175165.

(5) Cai JJ, Zhang M, Han T, Jiang HQ. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017, 96(37): e8057.

(6) Jiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med. 2017, 3(3): 165-168.

(7) Zhang K, Chang YN, Shi ZM, Han XH, Han YW, Yao QB, Hu ZM, Cui HM, Zheng LN, Han T, Hong W.ω-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP/TAZ degradation. Scientific Reports. 2016, 6: 30029. 

(8) Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PloS One. 2016, 11(9): e0163423.

(9) Liang J, Cai WJ, Han T, Jing L, Ma Z, Gao YT. The expression of thymosin beta4 in chronic hepatitis B combined nonalcoholic fatty liver disease. Medicine (Baltimore). 2016, 95(52): e5763.

(10) Jiang Y, Zhang ZG, Qi FX, Zhang Y, Han Y. Comparison of maintenance effect of probiotifcs and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. Chronic Diseases and Translational Medicine. 2016, 2(1): 34-41.

(11) Cai JJ, Han T, Nie CY, Jia XB, Liu Y, Zhu ZY, Gao YT. Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure. Clin Res Hepatol Gastroentero. 2016, 40(1): 41-50.

(12) Yin WL, Ye Q, Wang FM, Liang J, Xu BG, Zhang X, Zhang Q, Liu Y, Li G, Han T. ART score and hepatocellular carcinoma: An appraisal of its applicability. Clin Res Hepatol Gastroenterol, 2016, 40(6):705-714.

(13) Zhang Q, Han T, Li Y, et al. Predictors of progression into acute-on-chronic liver failure from acute deterioration of preexisting chronic liver disease. Hepatol Res. 2016, 46(4): 320-328.

(14) Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, Liu Y. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One. 2015, 10(3): e0122158.

(15) Liang J, Han T, Gao YT, Jing L, Ma Z. The expression of serum M30 and M65in chronic hepatitis B patients with non-alcoholic fatty liver disease.European Review for Medical and Pharmacological Sciences. 2015, 19 (21): 4123-4129.

(16) Zhang Q, Han T, Nie CY, et al. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. J Med Virol. 2015, 87(6): 1013-1021.

(17) Han LY, Han T, Nie CY, et al. Elevated mean platelet volume is associated with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. Clin Res Hepatol Gastroenterol. 2015, 39(3): 331-339.

(18) NieXH, Han T, Zhang L, Li Y, Liu H, Xiao SX, Li Y, Kang H, Liu SY. Comparison of effects of the pretreatment and treatment with RhIL-11 on acute liver failure induced by D-galactosamine. European Review for Medical and Pharmacological Science. 2014, 18(8): 1142-1150.

(19) Liu Y, Han T, Zhu ZY, Li Y. Thymosin beta4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient. Clin Res Hepatol Gastroenterol. 2014, 38(3): 310-317.

(20) Nie CY, Han T, Zhang L, Li Y, Liu H, Xiao SX, Li Y, Kang H, Liu SY. Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. J Viral Hepatitis. 2014, 21(1): 53-63.

7. Major Projects

(1) The National 13th 5-year Plan for Hepatitis Research，2017ZX10203201007， 2017/01-2020/12

(2).The National 12th 5-year Plan for Hepatitis Research，2012ZX10002004-011， 2015/01-2019/12

(3). The National Natural Science Foundation of China，81870429, 2019/01-2022/12

(4). The National Natural Science Foundation of China，81670558， 2017/01-2020/12